Showing 2621-2630 of 5909 results for "".
- Unity Biotechnology Presents Data Demonstrating Improvement in Retinal Vasculature and Function in Preclinical Models of Diabetic Retinopathy Eye Diseaseshttps://modernod.com/news/unity-biotechnology-presents-data-demonstrating-improvement-in-retinal-vasculature-and-function-in-preclinical-models-of-diabetic-retinopathy-eye-diseases/2479156/Unity Biotechnology announced preclinical data demonstrating that UBX1325, a novel senolytic small molecule inhibitor of Bcl-xL, improves retinal vasculature and is differentiated from anti-VEGF agents in preclinical models. Researchers show that inhibition of retinal Bcl-xL by UBX1325 selectivel
- New Alcon Data on Contact Lens, Dry Eye, and Ocular Health to Be Presented at ARVO 2021https://modernod.com/news/new-alcon-data-on-contact-lens-dry-eye-and-ocular-health-to-be-presented-at-arvo-2021/2479151/Alcon will present new data on several of its latest contact lens, dry eye, and ocular health innovations during the Association for Research in Vision and Ophthalmology (ARVO) 2021 virtual meeting taking place May 1-7. Alcon boasts a robust scientific showing at the meeting with nine accepted ab
- Eyemate System for Remote Glaucoma Management Obtains FDA Breakthrough Device Designationhttps://modernod.com/news/eyemate-system-for-remote-glaucoma-management-obtains-fda-breakthrough-device-designation/2479126/Implandata Ophthalmic Products announced today that its Eyemate system for digitally enabled remote patient monitoring and management of glaucoma has obtained Breakthrough Device Designation (BDD) from the US FDA. A BDD is only assigned for breakthrough technologies that have the potential to pro
- Johnson & Johnson Vision Receives Approval in Canada for First Drug-Releasing Contact Lens for Vision Correction and Allergic Eye Itchhttps://modernod.com/news/johnson-johnson-vision-receives-approval-in-canada-for-first-drug-releasing-contact-lens-for-vision-correction-and-allergic-eye-itch/2479117/Johnson & Johnson Vision received Health Canada approval for the first and only daily disposable contact lens for vision correction in patients who experience itchy allergy eyes due to allergic conjunctivitis: Acuvue Theravision with Ketotifen.1 The lens contains an H1 hista
- Amydis Completes Pre-IND Meeting With the FDA for the Development of a Retinal Tracer for the Diagnosis of Alpha-Synucleinopathieshttps://modernod.com/news/amydis-completes-pre-ind-meeting-with-the-fda-for-the-development-of-a-retinal-tracer-for-the-diagnosis-of-alpha-synucleinopathies/2479113/Amydis announced completion of pre-Investigational New Drug (IND) interaction with the FDA regarding the current development plan for a small-molecule retinal tracer for the diagnosis of α-synucleinopathies (ASYN). Funding provided by The Michael J. Fox Foundation for Parkinson’s
- Market Scope: US Cataract Pharmaceuticals Evolve in Drug Deliveryhttps://modernod.com/news/market-scope-us-cataract-pharmaceuticals-evolve-in-drug-delivery/2479107/US cataract surgeons showed a preference for incremental improvement in drug delivery over revolutionary change in the first full year for three new corticosteroid products to manage inflammation and pain after cataract surgery, according to a Market Scope report. The products hit the mark
- Ora Appoints David P. Bingaman, DVM, PhD, in Newly Created Chief Development Officer Positionhttps://modernod.com/news/ora-appoints-david-p-bingaman-dvm-phd-in-newly-created-chief-development-officer-position/2479097/Ora announced that David P. Bingaman, DVM, PhD, D. ACVO has joined the company in a newly created role of Chief Development Officer (CDO). Dr. Bingaman will oversee clinical and nonclinical activities that directly impact Ora’s customers around the world. Ora’s clinical research spans all
- RETINA-AI Health Awarded US Patent for AI Detection of Eye Diseasehttps://modernod.com/news/retina-ai-health-awarded-us-patent-for-ai-detection-of-eye-disease/2479088/RETINA-AI Health has been awarded a US patent on its artificial intelligence (AI) systems for autonomous detection of eye diseases from images. There are several eye diseases such as diabetic retinopathy, macular degeneration, and glaucoma for which segments of the general population need to be r
- ProtoKinetix Engages Multi-National Partner for Formulation of Topical Drug to Treat DED & Ocular Inflammationhttps://modernod.com/news/protokinetix-engages-multi-national-partner-for-formulation-of-topical-drug-to-treat-ded-ocular-inflammation/2479083/ProtoKinetix announced that it has engaged a global pharmaceutical company to develop the formulation as a topical ocular drug for the treatment of dry eye disease (DED) and ocular inflammation using AAGP. For the development of this drug for DED to date the company has completed:
- Lantronix Contributes to eSight Design, Enabling Individuals With Serious Visual Impairment to Seehttps://modernod.com/news/lantronix-contributes-to-esight-design-enabling-individuals-with-serious-visual-impairment-to-see/2479082/Lantronix announced that its engineering services team supported eSight Corp. in the development of an enhanced vision device that enables individuals with serious visual impairment to see. eSight was recently recognized as a manufacturer of the Best Wearable/Healthcare Hardware/Soft